<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: uncertainties", fill: "#9dc209"},
{source: "2: uncertainties", target: "2: operations", fill: "#9dc209"},
{source: "2: uncertainties", target: "4: difficult", fill: "#a9ba9d"},
{source: "4: difficult", target: "4: future performance", fill: "#a9ba9d"},
{source: "4: future performance", target: "4: operations", fill: "#a9ba9d"},
{source: "4: difficult", target: "6: Investors ", fill: "#5d8aa8"},
{source: "6: Investors ", target: "6: substantive", fill: "#5d8aa8"},
{source: "6: substantive", target: "6: on prior operations", fill: "#5d8aa8"},
{source: "6: on prior operations", target: "6: company as", fill: "#5d8aa8"},
{source: "6: company as", target: "6: investment", fill: "#5d8aa8"},
{source: "6: Investors ", target: "8: risks inherent", fill: "#dda0dd"},
{source: "8: risks inherent", target: "8: company with", fill: "#dda0dd"},
{source: "8: company with", target: "8: regulatory", fill: "#dda0dd"},
{source: "8: regulatory", target: "8: delays fluctuations", fill: "#dda0dd"},
{source: "8: delays fluctuations", target: "8: competition", fill: "#dda0dd"},
{source: "8: competition", target: "8: general strength", fill: "#dda0dd"},
{source: "8: general strength", target: "8: national economies", fill: "#dda0dd"},
{source: "8: national economies", target: "8: governmental regulation", fill: "#dda0dd"},
{source: "8: risks inherent", target: "12: accumulated", fill: "#915f6d"},
{source: "12: accumulated", target: "12: deficit through", fill: "#915f6d"},
{source: "12: deficit through", target: "12: December ", fill: "#915f6d"},
{source: "12: accumulated", target: "21: additional capital through", fill: "#ffae42"},
{source: "21: additional capital through", target: "21: collaborative arrangements", fill: "#ffae42"},
{source: "21: collaborative arrangements", target: "21: arrangements may", fill: "#ffae42"},
{source: "21: arrangements may", target: "21: relinquish", fill: "#ffae42"},
{source: "21: relinquish", target: "21: greater rights", fill: "#ffae42"},
{source: "21: greater rights", target: "21: technologies", fill: "#ffae42"},
{source: "21: technologies", target: "21: protocols than", fill: "#ffae42"},
{source: "21: protocols than", target: "21: might otherwise", fill: "#ffae42"},
{source: "21: additional capital through", target: "22: raise additional capital through", fill: "#ff004f"},
{source: "22: raise additional capital through", target: "22: securities convertible into equity further dilution", fill: "#ff004f"},
{source: "22: securities convertible into equity further dilution", target: "22: then existing", fill: "#ff004f"},
{source: "22: then existing", target: "22: stockholders", fill: "#ff004f"},
{source: "22: raise additional capital through", target: "34: largely dependent upon referrals", fill: "#e3ff00"},
{source: "34: largely dependent upon referrals", target: "34: facilities", fill: "#e3ff00"},
{source: "34: facilities", target: "34: technology", fill: "#e3ff00"},
{source: "34: technology", target: "34: protocols by physicians", fill: "#e3ff00"},
{source: "34: largely dependent upon referrals", target: "41: accounting staff", fill: "#009e60"},
{source: "41: accounting staff", target: "41: obligations as", fill: "#009e60"},
{source: "41: obligations as", target: "41: comply with", fill: "#009e60"},
{source: "41: comply with", target: "41: requirements", fill: "#009e60"},
{source: "41: requirements", target: "41: SarbanesOxley Act ", fill: "#009e60"},
{source: "41: SarbanesOxley Act ", target: "41: regulations", fill: "#009e60"},
{source: "41: regulations", target: "41: will continue", fill: "#009e60"},
{source: "41: will continue", target: "41: significant demands on", fill: "#009e60"},
{source: "41: significant demands on", target: "41: accounting staff on", fill: "#009e60"},
{source: "41: accounting staff on", target: "41: financial accounting", fill: "#009e60"},
{source: "41: financial accounting", target: "41: internal controls", fill: "#009e60"},
{source: "41: accounting staff", target: "89: personal injury", fill: "#c19a6b"},
{source: "89: personal injury", target: "89: which could", fill: "#c19a6b"},
{source: "89: which could", target: "89: liabilities", fill: "#c19a6b"},
{source: "89: liabilities", target: "89: insurance coverage", fill: "#c19a6b"},
{source: "89: insurance coverage", target: "89: significant medical treatments", fill: "#c19a6b"},
{source: "89: significant medical treatments", target: "89: protocols involve", fill: "#c19a6b"},
{source: "89: protocols involve", target: "89: serious injury", fill: "#c19a6b"},
{source: "89: personal injury", target: "START_HERE", fill: "#c19a6b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Research and Consulting Services</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Investigate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Human illness</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Difficult_Woman">A Difficult Woman</a></td>
      <td>A Difficult Woman is an Australian television series which screened in 1998 on the ABC. The three part series starred Caroline Goodall, in the title role of a woman whose best friend is murdered and is determined to find out why. It was written by Nicholas Hammond and Steven Vidler and directed by Tony Tilse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_to_Cure">Difficult to Cure</a></td>
      <td>Difficult to Cure is the fifth studio album by the British hard rock band Rainbow, released in 1981. The album marked the further commercialization of the band's sound, with Ritchie Blackmore once describing at the time his appreciation of the band Foreigner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/For_Love_or_Money_(2014_film)">For Love or Money (2014 film)</a></td>
      <td>For Love or Money (Chinese: 露水红颜) is a Chinese romance film based on Hong Kong novelist Amy Cheung's 2006 novel of the same name. The film was directed by Gao Xixi and starring Liu Yifei and Rain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_Loves">Difficult Loves</a></td>
      <td>Difficult Loves (Italian: Gli amori difficili) is a 1970 short story collection by Italo Calvino. It concerns love and the difficulty of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_(song)">Difficult (song)</a></td>
      <td>"Difficult" is the fourth single from French-American recording artist Uffie's debut album, Sex Dreams and Denim Jeans. The single was produced by Uffie's label-mate and friend SebastiAn and was released by Ed Banger Records, Because Music and Elektra Records on October 18, 2010.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stockholder_of_record">Stockholder of record</a></td>
      <td>Stockholder of record is the name of an individual or entity shareholder that an issuer carries in its shareholder register as the registered holder (not necessarily the beneficial owner) of the issuer's securities. Dividends and other distributions are paid only to shareholders of record.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jessica_Stockholder">Jessica Stockholder</a></td>
      <td>Jessica Stockholder (born 1959) is a Canadian-American artist known for site-specific installation works and sculptures that are often described as "paintings in space." She came to prominence in the early 1990s with monumental works that challenged boundaries between artwork and display environment as well as between pictorial and physical experience. Her art often presents a "barrage" of bold colors, textures and everyday objects, incorporating floors, walls and ceilings and sometimes spilling out of exhibition sites.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Derivative_suit">Derivative suit</a></td>
      <td>A shareholder derivative suit is a lawsuit brought by a shareholder on behalf of a corporation against a third party. Often, the third party is an insider of the corporation, such as an executive officer or director.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Friedman_doctrine">Friedman doctrine</a></td>
      <td>The Friedman doctrine, also called shareholder theory or stockholder theory, is a normative theory of business ethics advanced by economist Milton Friedman which holds that the social responsibility of business is to increase its profits. This shareholder primacy approach views shareholders as the economic engine of the organization and the only group to which the firm is socially responsible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_insurance">Liability insurance</a></td>
      <td>Liability insurance (also called third-party insurance) is a part of the general insurance system of risk financing to protect the purchaser (the "insured") from the risks of liabilities imposed by lawsuits and similar claims and protects the insured if the purchaser is sued for claims that come within the coverage of the insurance policy.\nOriginally, individual companies that faced a common peril formed a group and created a self-help fund out of which to pay compensation should any member incur loss (in other words, a mutual insurance arrangement).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>HYTHIAM INC      ITEM 1A RISK FACTORS          You <font color="blue">should carefully</font> consider and evaluate all of the information in     this  report,  including  the  risk  factors  listed  below</td>
    </tr>
    <tr>
      <td>Risks and     <font color="blue">uncertainties</font>  in addition to those we describe below, that may not be     presently known to us, or that we currently believe are immaterial, may also     harm  our  business  and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of these risks occurs, our     business, results of <font color="blue">operations</font> and <font color="blue"><font color="blue">financial condition</font> could</font> be harmed, the     price of our <font color="blue"><font color="blue">common stock</font> could decline</font>, and <font color="blue">future events</font> and <font color="blue">circumstances</font>     <font color="blue">could differ <font color="blue">significant</font>ly from</font> those anticipated in the forward-looking     <font color="blue">statements contained</font> in this report</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to Our Business       We have a limited operating history, making it <font color="blue">difficult</font> to evaluate our     <font color="blue">future performance</font>          We  have  a  limited  history  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We were formed in     <font color="blue">February </font>2003 and commenced <font color="blue">operations</font> in June 2003</td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font>have limited     <font color="blue">substantive</font>  financial information on prior <font color="blue">operations</font> to evaluate the     <font color="blue">company as</font> an <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">potential must</font> be viewed in light of the     problems, expenses, <font color="blue">difficult</font>ies, delays and <font color="blue">complications often encountered</font>     in the operation of a new business</td>
    </tr>
    <tr>
      <td>We will be subject to the <font color="blue">risks inherent</font>     in the ownership and operation of a <font color="blue">company with</font> a limited operating history     such  as  <font color="blue">regulatory</font>  setbacks  and  delays, fluctuations in expenses,     <font color="blue">competition</font>, the <font color="blue">general strength</font> of regional and <font color="blue">national economies</font>, and     <font color="blue"><font color="blue">government</font>al regulation</font></td>
    </tr>
    <tr>
      <td>Any failure to <font color="blue"><font color="blue">successfully</font> address</font> these risks and     <font color="blue">uncertainties</font> would seriously harm our business and prospects</td>
    </tr>
    <tr>
      <td>We expect to continue to incur operating losses, and if we are not able to     <font color="blue">raise <font color="blue">necessary</font> <font color="blue"><font color="blue">additional</font> funds</font></font> we may have to reduce or stop <font color="blue">operations</font>          We have not <font color="blue">generated <font color="blue">significant</font> revenues</font> or become profitable, may     never do so, and may not <font color="blue">generate sufficient</font> working capital to cover the     cost  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues since commencement</font> of <font color="blue">operations</font> in     June 2003 were dlra1dtta4 million through <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our <font color="blue">accumulated</font>     <font color="blue">deficit through</font> <font color="blue">December </font>31, 2005 was dlra39dtta4 million</td>
    </tr>
    <tr>
      <td>We anticipate that     operating <font color="blue">deficits <font color="blue">will continue</font></font> for at least the <font color="blue">next twelve months</font> of our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because many of our costs <font color="blue">generally</font> will increase, the cost of     operating the <font color="blue">company will exceed</font> the <font color="blue">income therefrom during</font> this period</td>
    </tr>
    <tr>
      <td>No party has guaranteed to <font color="blue">advance <font color="blue"><font color="blue">additional</font> funds</font></font> to us to provide for any     such  operating  deficits</td>
    </tr>
    <tr>
      <td>Our cash and <font color="blue">marketable securities totaled</font>     <font color="blue">approximately</font> dlra47 million as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our fourth quarter 2005     <font color="blue">net cash burn rate</font> was <font color="blue">approximately</font> dlra2dtta6 million per month</td>
    </tr>
    <tr>
      <td>We expect to     increase our <font color="blue">monthly expenditures over</font> the <font color="blue">next twelve months</font> as we increase     staff, commence marketing <font color="blue">activities</font>, expand the number of licensees and     provide  funding  for  research  studies</td>
    </tr>
    <tr>
      <td>If our revenues do not meet     <font color="blue"><font color="blue">expectation</font>s</font> and our <font color="blue">expenses continue</font> to increase, our <font color="blue">cash reserves will</font>     be exhausted in fifteen to <font color="blue">eighteen months</font>, and we will be required to seek     <font color="blue"><font color="blue">additional</font> funds</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may seek <font color="blue">additional</font> funding through public</font> or <font color="blue">private financings</font> or     <font color="blue">collaborative</font>  <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>If  we obtain <font color="blue"><font color="blue">additional</font> capital through</font>     <font color="blue">collaborative</font> <font color="blue">arrangements</font>, these <font color="blue">arrangements</font> may require us to <font color="blue">relinquish</font>     <font color="blue">greater rights</font> to our <font color="blue">technologies</font> and <font color="blue">protocols than</font> we <font color="blue">might otherwise</font>     have done</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue"><font color="blue">additional</font> capital through</font> the sale of equity, or     securities convertible into equity, further dilution to our <font color="blue">then existing</font>     <font color="blue">stockholders</font>  will  result</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue"><font color="blue">additional</font> capital through</font> the     incurrence of debt, our business may be <font color="blue">affected by</font> the amount of leverage     we  incur, and our <font color="blue">borrowings may</font> subject us to <font color="blue">restrictive covenants</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">funding may</font> not be available to us on acceptable terms, or at     all</td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">adequate financing on</font> a <font color="blue">timely basis</font>, we may     be required to delay, reduce or stop <font color="blue">operations</font>, any of <font color="blue">which would</font> have a     material adverse effect on our business</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on <font color="blue">third party</font> <font color="blue">healthcare providers</font> licensing</font> and using our     protocols, and if they delay or fail to do so our revenues and earnings     could be <font color="blue"><font color="blue">adversely</font> affected</font>          Only a physician may treat or supervise the treatment of patients using     the PROMETA^™ protocols, which requires us to <font color="blue"><font color="blue">enter into</font> licenses with</font>     physicians,  hospitals, properly equipped outpatient settings or other     <font color="blue">treatment <font color="blue">facilities</font></font> in order to <font color="blue">provide convenient treatment access points</font>     for patients</td>
    </tr>
    <tr>
      <td>Our revenues are therefore <font color="blue">dependent</font> to a <font color="blue"><font color="blue">significant</font> degree</font>     upon the <font color="blue">relationships</font> we can establish with physicians, hospitals and other     <font color="blue">healthcare <font color="blue">facilities</font></font> to license our protocols for treating their patients</td>
    </tr>
    <tr>
      <td>In 2005, <font color="blue">approximately</font> 63prca of our revenues were <font color="blue">derived from only three</font>     licensees</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had <font color="blue">entered into licensing <font color="blue">agreement</font>s</font>     for 32 sites throughout the                                         20       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font><font color="blue">United States</font>, of which 25 were added in 2005</td>
    </tr>
    <tr>
      <td>The number of patients who     were <font color="blue">treated by</font> our licensees in 2005 was <font color="blue">approximately</font> 215, and in the last     six months of 2005 was <font color="blue">approximately</font> 135</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>rollout is anticipated     to  be  <font color="blue">dependent</font>  on  our ability to negotiate and conclude licensing     <font color="blue"><font color="blue">agreement</font>s with such <font color="blue">healthcare providers</font> across</font> the country and their     ability  to  <font color="blue">generate patients</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">enter into</font> similar     <font color="blue">arrangements</font> with these <font color="blue"><font color="blue">additional</font> <font color="blue">healthcare providers</font></font> for any reason, that     <font color="blue">would <font color="blue">significant</font>ly limit</font> our <font color="blue">growth potential</font> and <font color="blue">negatively impact</font> our     business prospects</td>
    </tr>
    <tr>
      <td>In addition, if physicians, hospitals and healthcare     providers do not <font color="blue">attract sufficient patient volume</font> and revenue they may not     be willing to continue to offer our protocols</td>
    </tr>
    <tr>
      <td>The success of our protocols is largely <font color="blue">dependent</font> upon referrals of     patients to <font color="blue">facilities</font> that license our <font color="blue">technology</font> and upon the use of our     <font color="blue"><font color="blue">protocols by</font> physicians</font> in treating their patients</td>
    </tr>
    <tr>
      <td>There is <font color="blue">no requirement</font>     for  physicians to refer their patients to <font color="blue">facilities</font> that license our     protocols, or to use our protocols in treating their patients</td>
    </tr>
    <tr>
      <td>They are free     to <font color="blue">refer patients</font> to any other substance <font color="blue"><font color="blue">dependence treatment</font> service</font>,     program or <font color="blue">facility</font>, and to treat their <font color="blue">patients using whatever method</font> they     determine to be in the patients’ <font color="blue">best interests</font></td>
    </tr>
    <tr>
      <td>The failure of physicians     to treat a sufficient number of patients using our protocols, or to refer     patients to <font color="blue">facilities</font> that use our protocols, or the loss of physicians     that  use  our  protocols  would have a material adverse effect on our     <font color="blue">operations</font> and <font color="blue">could <font color="blue">adversely</font> affect</font> our revenues and earnings</td>
    </tr>
    <tr>
      <td>We may fail to <font color="blue"><font color="blue">successfully</font> manage</font> and maintain the growth of our business,     which <font color="blue">could <font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font>          As  we  continue  expanding  our  <font color="blue">operations</font>, sales and marketing     <font color="blue">activities</font>, this <font color="blue">expansion could put <font color="blue">significant</font></font> strain on our <font color="blue">management</font>,     operational and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">manage future growth</font>, we will need     to continue to hire, train and manage <font color="blue">additional</font> employees, particularly a     specially-trained sales force to market our protocols</td>
    </tr>
    <tr>
      <td><font color="blue">Concurrent </font>with     expanding  our  operational  and marketing <font color="blue">activities</font>, we will also be     increasing  our  research  and  <font color="blue">development</font>  <font color="blue">activities</font>, including the     <font color="blue">development</font> of protocols for other types of <font color="blue">addiction</font>s, with the <font color="blue">expectation</font>     of <font color="blue">ultimately commercializing</font> those products</td>
    </tr>
    <tr>
      <td>We have maintained a small     financial and <font color="blue"><font color="blue">accounting</font> staff</font>, and our reporting <font color="blue">obligations as</font> a public     company,  as  well  as our need to <font color="blue">comply with</font> the <font color="blue">requirements</font> of the     Sarbanes-Oxley Act of 2002, the rules and <font color="blue">regulations</font> of the SEC and The     Nasdaq National Market, <font color="blue">will continue</font> to place <font color="blue"><font color="blue">significant</font> demands on</font> our     financial and <font color="blue"><font color="blue">accounting</font> staff</font>, on our financial, <font color="blue">accounting</font> and information     systems  and on our <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td>As we grow, we will need to add     <font color="blue">additional</font>  <font color="blue">accounting</font>  staff  and  continue to improve our financial,     <font color="blue">accounting</font> and information systems and <font color="blue">internal controls</font> in order to fulfill     our  reporting  <font color="blue">responsibilities</font> and to support expected growth in our     business</td>
    </tr>
    <tr>
      <td>Our  current and planned personnel, systems, procedures and     <font color="blue">controls may</font> not be adequate to support our anticipated growth or <font color="blue">management</font>     may not be able to <font color="blue">effective</font>ly hire, train, retain, motivate and manage     required personnel</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">manage growth <font color="blue">effective</font>ly could limit</font> our     ability to achieve our marketing and <font color="blue">commercialization goals</font> or to satisfy     our reporting and other <font color="blue">obligations as</font> a <font color="blue">public company</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">treatment protocols</font> may not be <font color="blue">as <font color="blue">effective</font> as</font> we believe them to be,     <font color="blue"><font color="blue">which could</font> limit</font> or <font color="blue">prevent us from</font> maintaining revenues          Our belief in the efficacy of our <font color="blue">treatment protocols</font> is <font color="blue">based on</font> a     limited number of unpublished studies, primarily in Spain, and our limited     initial experience with a small number of patients <font color="blue">in the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Such results may not be <font color="blue">statistically <font color="blue">significant</font></font>, have not <font color="blue">been subjected</font>     to close <font color="blue">scientific scrutiny</font>, and may not be <font color="blue">indicative</font> of the long-term     future  performance and safety of our protocols</td>
    </tr>
    <tr>
      <td><font color="blue">Controlled </font>scientific     studies,  including those that have been announced and planned for the     future, may yield results that are unfavorable or <font color="blue">demonstrate</font> that our     protocols  are  not  <font color="blue">clinically</font>  <font color="blue">effective</font>  or safe</td>
    </tr>
    <tr>
      <td>While we have not     experienced <font color="blue">such problems</font> to date, if the <font color="blue">initially indicated</font> results cannot     be <font color="blue"><font color="blue">successfully</font> replicated</font> or maintained over time, <font color="blue">utilization</font> of our     <font color="blue">protocols could decline substantially</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">marketing efforts may</font> not result in <font color="blue">acceptance</font> of our protocols in the     marketplace, which <font color="blue">could <font color="blue">adversely</font> affect</font> our revenues and earnings          While we have been able to <font color="blue">generate initial interest</font> in our protocols     among a limited number of <font color="blue">healthcare providers</font>, there can be no assurance     that our efforts or the efforts of <font color="blue">others will</font> be successful in fostering     <font color="blue">acceptance</font> of our protocols in the <font color="blue">target markets</font></td>
    </tr>
    <tr>
      <td>If our marketing and     <font color="blue">promotional efforts</font> are not <font color="blue">as successful as</font> we expect them to be, the     likelihood  of expending all of our <font color="blue">funds prior</font> to reaching a level of     <font color="blue"><font color="blue">profitability</font> will</font> be increased</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>     Marketplace  <font color="blue">acceptance</font>  of our <font color="blue"><font color="blue">protocols may</font> largely depend upon</font>     <font color="blue">healthcare providers</font>’ <font color="blue">interpretation</font> of our limited data, the results of     pending  studies,  or  upon  reviews  and reports that may be given by     in<font color="blue">dependent</font> researchers</td>
    </tr>
    <tr>
      <td>We have awarded and are in the process of awarding     <font color="blue">additional</font>  unrestricted  grants  to  academic and <font color="blue">affiliated research</font>     <font color="blue">institutions</font> and other <font color="blue">research <font color="blue">organizations</font> interested</font> in conducting     <font color="blue">research studies</font> of our PROMETA protocols</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we have     committed to spending <font color="blue">approximately</font> dlra4dtta4 million over the next twenty-four     months to <font color="blue">fund unrestricted grants</font></td>
    </tr>
    <tr>
      <td>In the event such research does not give     our treatment <font color="blue">technology</font> high approval ratings, it is unlikely we will be     able to achieve <font color="blue">significant</font> market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Our  industry is <font color="blue">highly <font color="blue">competitive</font></font>, and we may not be able to compete     <font color="blue">successfully</font>          The  healthcare business in general, and the substance dependence     treatment business in particular, are <font color="blue">highly <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Hospitals </font>and     <font color="blue">healthcare providers</font> that treat substance dependence are <font color="blue">highly <font color="blue">competitive</font></font>,     and we must convince them that they will benefit by use of our protocols</td>
    </tr>
    <tr>
      <td>We     <font color="blue">will compete with</font> many types of substance <font color="blue"><font color="blue">dependence treatment</font> methods</font>,     <font color="blue">treatment <font color="blue">facilities</font></font> and other <font color="blue">service providers</font>, many of whom are more     established and <font color="blue">better funded than</font> we are</td>
    </tr>
    <tr>
      <td>Many of these other treatment     methods—most of which involve only a single drug—and <font color="blue">facilities</font> are well     established in the <font color="blue">same markets</font> we will target, have substantial sales     volume,  and  are provided and <font color="blue"><font color="blue">marketed by</font> companies with</font> much greater     <font color="blue">financial resources</font>, <font color="blue">facilities</font>, organization, reputation and experience     than we have</td>
    </tr>
    <tr>
      <td>There are a number of companies developing or <font color="blue">marketing <font color="blue">medications</font></font> for     <font color="blue">reducing craving</font> in the treatment of <font color="blue">alcoholism</font></td>
    </tr>
    <tr>
      <td>These include:       •   The <font color="blue"><font color="blue">addiction</font> medication naltrexone</font>, an <font color="blue">opiate <font color="blue">receptor antagonist</font></font>, is     <font color="blue">marketed by</font> a number of generic pharmaceutical companies as well as under     the trade name ReVia^® by Bristol Myers Squib, for treatment of alcohol     dependence</td>
    </tr>
    <tr>
      <td>However, <font color="blue">naltrexone must</font> be <font color="blue"><font color="blue">administered</font> on</font> a chronic or     <font color="blue">continuing basis</font> and is <font color="blue">associated with relatively high rates</font> of side     effects, including nausea</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Alkermes </font>is developing a long-acting injectable form of naltrexone,     VIVITROL™,  intended  to  be  <font color="blue">administered</font>  by a <font color="blue">physician via monthly</font>     <font color="blue">injections</font></td>
    </tr>
    <tr>
      <td>The company reported results from a phase III <font color="blue">clinical study</font>     indicating that in the overall study population, <font color="blue">patients treated</font> with     VIVITROL 380 mg experienced <font color="blue">approximately</font> a 25prca reduction in the rate of     <font color="blue">heavy drinking relative</font> to placebo</td>
    </tr>
    <tr>
      <td>Alkermes, in <font color="blue">partnership</font> with Cephalon,     reports it intends to launch VIVITROL in the <font color="blue">second quarter</font> of 2006, pending     final FDA approval</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Forest Laboratories </font>holds the license in the US to market Campral^®     Delayed-Release Tablets (acamprosate calcium), approved by the FDA in 2004</td>
    </tr>
    <tr>
      <td><font color="blue">Acamprosate </font>is an NMDA <font color="blue">receptor antagonist</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">product must</font> be <font color="blue">taken two</font> to     three  <font color="blue">times per day on</font> a chronic or long-term basis</td>
    </tr>
    <tr>
      <td>Clinical studies     supported  the  <font color="blue">effective</font>ness  in  the  maintenance  of abstinence for     alcohol-<font color="blue">dependent</font> patients who had undergone inpatient detoxification and     were already <font color="blue">abstinent</font> from alcohol, but the product was not <font color="blue">effective</font> for     patients who had not <font color="blue">undergone detoxification</font> and who were not <font color="blue">abstinent</font>     prior to treatment</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>     We see these <font color="blue">products as</font> being <font color="blue"><font color="blue">potentially</font> useful during</font> the continuing     <font color="blue">care phase</font> of <font color="blue">treatment following <font color="blue">treatment using</font></font> <font color="blue">the PROMETA </font>protocols, but     not being directly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>To the best of our knowledge, there are no     <font color="blue">treatment protocols</font> or <font color="blue">medications</font> approved, marketed or in <font color="blue">development</font>     within the US that reduce the cravings for cocaine, <font color="blue">methamphetamine</font> or     other <font color="blue">additive <font color="blue">prescription</font> psychostimulants</font></td>
    </tr>
    <tr>
      <td>However, our <font color="blue"><font color="blue">competitors</font> may</font>     develop and introduce <font color="blue">new processes</font> and products that are equal or superior     to our protocols in treating substance <font color="blue">dependencies</font></td>
    </tr>
    <tr>
      <td>Accordingly, we may be     <font color="blue">adversely</font> <font color="blue">affected by</font> any <font color="blue">new processes</font> and <font color="blue">technology</font> developed by our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">approximately</font> 13cmam000 <font color="blue">facilities</font> reporting to the Substance     Abuse and Mental Health Services Administration that provide substance abuse     treatment  on an inpatient or <font color="blue">outpatient basis</font></td>
    </tr>
    <tr>
      <td>Well <font color="blue">known examples</font> of     residential  treatment  programs  include the Betty Ford Center, Caron     Foundation, Hazelden and Sierra Tucson</td>
    </tr>
    <tr>
      <td>In addition, individual physicians     may provide substance <font color="blue">dependence treatment</font> in the course of their practices</td>
    </tr>
    <tr>
      <td>There  are  several  points of resistance to <font color="blue">penetrating</font> the substance     <font color="blue">dependence treatment</font> market</td>
    </tr>
    <tr>
      <td>First, there is the <font color="blue">historical focus on</font> the use     of  psychological  or  <font color="blue">behavioral</font>  therapies  as opposed to medical or     <font color="blue">physiological <font color="blue">treatments</font></font> for substance dependence</td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font>providers and     <font color="blue">potential <font color="blue">patients may</font></font> be resistant to the transition of treating substance     <font color="blue">dependence as</font> a <font color="blue">disease <font color="blue">rather than</font> as</font> a <font color="blue">behavioral</font> aberration</td>
    </tr>
    <tr>
      <td>Second,     healthcare  <font color="blue">providers may</font> be reluctant to use our <font color="blue">protocols due</font> to the     absence of <font color="blue">published clinical studies supporting</font> their efficacy</td>
    </tr>
    <tr>
      <td><font color="blue">Research     </font>studies of <font color="blue">the PROMETA </font><font color="blue">protocols may</font> not lead to acceptable results or the     results  may  not  be  published</td>
    </tr>
    <tr>
      <td>If we are unable to penetrate these     substantial barriers to entry we may not be able to <font color="blue">successfully</font> implement     our business plan</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on <font color="blue">key personnel</font></font>, the loss of <font color="blue"><font color="blue">which could</font> impact</font> the ability to     manage our business          Our <font color="blue">future success depends on</font> the performance of our senior <font color="blue">management</font>     and our <font color="blue">key professional personnel</font></td>
    </tr>
    <tr>
      <td>It therefore depends to a <font color="blue">significant</font>     extent  on  retaining  the  services of our <font color="blue">key executive officers</font>, in     particular our Chairman and Chief Executive Officer, Terren S Peizer, our     Director and Chief Administrative Officer, Richard Anderson, our Director     and Chief Operating Officer, Anthony M LaMacchia, and our Chief Financial     Officer, Chuck Timpe</td>
    </tr>
    <tr>
      <td>Each of these key <font color="blue">executives</font> is party to an <font color="blue">employment</font>     <font color="blue"><font color="blue">agreement</font> which</font>, subject to <font color="blue">termination</font> for cause or good reason, has a     <font color="blue">remaining term</font> of two to <font color="blue">three years</font></td>
    </tr>
    <tr>
      <td>While we believe our <font color="blue">relationships</font>     with our <font color="blue">executives</font> are good and do not anticipate any of them leaving in     the near future, the loss of the services of Mr</td>
    </tr>
    <tr>
      <td>While  we have not experienced any problems in     attracting and retaining <font color="blue">desirable employees</font>, our success is <font color="blue">dependent</font> upon     our  ability  to  continue to attract and retain qualified <font color="blue">management</font>,     professional, <font color="blue">administrative</font> and <font color="blue">sales personnel</font> to support our future     growth</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">personal injury</font> claims, <font color="blue">which could</font> result in substantial     <font color="blue">liabilities</font> that may exceed our <font color="blue">insurance coverage</font>          All <font color="blue">significant</font> medical <font color="blue">treatments</font> and procedures, including treatment     utilizing our protocols, involve the risk of <font color="blue">serious injury</font> or death</td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>under proper medical supervision, withdrawal from alcohol may cause severe     <font color="blue">physical reactions</font></td>
    </tr>
    <tr>
      <td>While we do not <font color="blue">treat patients</font> or determine whether     <font color="blue">treatment using</font> our protocols is <font color="blue">appropriate</font> for any <font color="blue">particular patient</font>, and     have not been the subject of any <font color="blue">personal injury</font> claims for <font color="blue">patients treated</font>     <font color="blue">by providers using</font> our protocols, our business entails an <font color="blue">inherent risk</font> of     claims for personal injuries, which are subject to the <font color="blue">attendant risk</font> of     substantial <font color="blue">damage awards</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control whether</font> individual physicians     <font color="blue">will properly</font> select patients, apply the <font color="blue">appropriate</font> standard of care, or     conform to our protocols in determining how to treat their patients</td>
    </tr>
    <tr>
      <td>A     <font color="blue">significant</font>  source  of  potential  <font color="blue">liability</font> is negligence or alleged     <font color="blue">negligence by physicians <font color="blue">treating patients using</font></font> our protocols</td>
    </tr>
    <tr>
      <td>While our     <font color="blue"><font color="blue">agreement</font>s typically</font> require them to <font color="blue">indemnify us</font> for their negligence,     there can be no assurance they will be willing and <font color="blue">financially able</font> to do so     if  claims are made</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">license <font color="blue">agreement</font>s</font> require us to     indemnify physicians, hospitals or their <font color="blue">affiliates</font> for losses resulting     from our negligence</td>
    </tr>
    <tr>
      <td>There can be no assurance that a future claim or claims     will not be successful or, including the cost of legal defense, will not     exceed the limits of available <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">insurance coverage</font> for up to dlra5 million per year for     <font color="blue">personal injury</font> claims</td>
    </tr>
    <tr>
      <td>We may not be able to maintain adequate <font color="blue">liability</font>     insurance, in <font color="blue">accordance with</font> standard industry practice, with <font color="blue">appropriate</font>     coverage <font color="blue">based on</font> the nature and risks of our business, at acceptable costs     and on favorable terms</td>
    </tr>
    <tr>
      <td>Insurance carriers are often reluctant to provide     <font color="blue">liability</font> insurance for <font color="blue">new <font color="blue">healthcare services</font> companies</font> and products due     to the                                         23       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>limited claims history for <font color="blue">such companies</font> and products</td>
    </tr>
    <tr>
      <td>In addition, based     <font color="blue">on current insurance markets</font>, we expect that <font color="blue">liability</font> insurance will be     more <font color="blue">difficult</font> to obtain and that <font color="blue">premiums will increase over</font> time and as     the volume of <font color="blue">patients treated</font> with our <font color="blue">protocols increases</font></td>
    </tr>
    <tr>
      <td>In the event of     <font color="blue">litigation</font>, <font color="blue">regardless</font> of its merit or eventual outcome, or an <font color="blue">award against</font>     us  during  a time when we have <font color="blue">no available insurance</font> or insufficient     insurance, we may sustain <font color="blue">significant</font> losses of our operating <font color="blue">capital which</font>     <font color="blue">may substantially impair</font> or destroy the <font color="blue">investment</font>s of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> and third-party payors fail to <font color="blue">provide coverage</font> and adequate     <font color="blue">payment rates</font> for <font color="blue">treatment using</font> our protocols, our revenue and prospects     for <font color="blue"><font color="blue">profitability</font> will</font> be harmed          Our <font color="blue">future revenue growth will depend</font> in part upon the <font color="blue">availability</font> of     <font color="blue"><font color="blue">reimbursement</font> from</font> third-party payors for <font color="blue">treatment providers using</font> our     protocols</td>
    </tr>
    <tr>
      <td>Such third-party payors include <font color="blue">government</font> health programs such     as Medicare and Medicaid, managed care providers, private health insurers     and  other  <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>These  third-party payors are <font color="blue">increasingly</font>     attempting to contain healthcare costs by demanding price discounts or     rebates and <font color="blue">limiting both coverage on which procedures</font> they will pay for and     the amounts that they will pay for <font color="blue">new procedures</font></td>
    </tr>
    <tr>
      <td>We     might need to <font color="blue">conduct studies</font> in order to <font color="blue">demonstrate</font> the cost-<font color="blue">effective</font>ness     of <font color="blue">treatment using</font> our protocols to such payors’ satisfaction</td>
    </tr>
    <tr>
      <td>Such studies     might require us to commit a <font color="blue">significant</font> amount of <font color="blue">management</font> time and     financial and other resources</td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>third-party <font color="blue">reimbursement</font> might not     be available to <font color="blue">enable us</font> to realize an <font color="blue">appropriate</font> return on <font color="blue">investment</font> in     research and product <font color="blue">development</font>, and the lack of <font color="blue">such <font color="blue">reimbursement</font> could</font>     have a material adverse effect on our <font color="blue">operations</font> and <font color="blue">could <font color="blue">adversely</font> affect</font>     our revenues and earnings</td>
    </tr>
    <tr>
      <td>Our planned <font color="blue">international</font> <font color="blue">operations</font> may be subject to <font color="blue">foreign regulation</font>,     and the success of our foreign <font color="blue">operations</font> will depend on many factors</td>
    </tr>
    <tr>
      <td>While we will establish policies and procedures that we believe will     be sufficient to ensure that we operate in substantial <font color="blue">compliance with</font>     applicable foreign laws, <font color="blue">regulations</font> and <font color="blue">requirements</font>, the criteria are     <font color="blue">often vague</font> and subject to change and <font color="blue">interpretation</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font>     <font color="blue">operations</font> may become the subject of foreign <font color="blue">regulatory</font>, civil, criminal or     other <font color="blue"><font color="blue">investigation</font>s</font> or <font color="blue">proceedings</font>, and our <font color="blue">interpretation</font>s of applicable     laws and <font color="blue">regulations</font> may be challenged</td>
    </tr>
    <tr>
      <td>The defense of any <font color="blue">such challenge</font>     could result in substantial cost and a diversion of <font color="blue">management</font>’s time and     attention</td>
    </tr>
    <tr>
      <td>Thus, any <font color="blue">such challenge</font> could have a material adverse effect on     our  <font color="blue">international</font>  business  and our plan to expand our <font color="blue">international</font>     <font color="blue">operations</font>, <font color="blue">regardless</font> of whether it ultimately is successful</td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">comply with</font> any applicable <font color="blue">international</font> laws, or a de<font color="blue">termination</font> is made     that we have failed to <font color="blue">comply with</font> these laws, our <font color="blue">financial condition</font> and     results of <font color="blue">operations</font>, including our domestic <font color="blue">operations</font>, could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>In <font color="blue">addition private pay healthcare system</font> in Europe is not as developed     as in the US and as a result it may be more <font color="blue">difficult</font> to convince patients     in these countries to pay or to pay substantial amounts for treatment</td>
    </tr>
    <tr>
      <td>We     will be reliant on <font color="blue">relationships</font> that we <font color="blue">establish with local companies</font>,     thought leaders and <font color="blue">government</font>s</td>
    </tr>
    <tr>
      <td>There can be no assurance we will be able     to establish these <font color="blue">relationships</font>, maintain them or that the <font color="blue">partners will</font>     retain their influence in the market</td>
    </tr>
    <tr>
      <td>It may take <font color="blue">longer than</font> we expect to     commence <font color="blue">operations</font> or to operate our business <font color="blue">at profitable levels as</font> we do     not have the established <font color="blue">relationships</font> and knowledge of the <font color="blue">regulations</font> and     business practices in the markets we are entering</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Intellectual Property       We may not be able to <font color="blue"><font color="blue">adequately</font> protect</font> the <font color="blue">proprietary</font> <font color="blue">treatment protocols</font>     which are the core of our business          We consider the protection of our <font color="blue">proprietary</font> <font color="blue">treatment protocols</font> to be     critical to our business prospects</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>We  obtained the rights to some of our most <font color="blue">significant</font> patent-pending     <font color="blue">technologies</font> through a license <font color="blue"><font color="blue">agreement</font> which</font> is subject to a number of     <font color="blue">conditions</font> and <font color="blue">restrictions</font>, and a breach or <font color="blue">termination</font> of that <font color="blue">agreement</font>     could <font color="blue">significant</font>ly impact our ability to use and develop our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We currently have no issued US <font color="blue">patents covering</font> our PROMETA protocols</td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">patent <font color="blue">applications</font></font> we have filed and <font color="blue">licensed may</font> not issue     as patents, and any <font color="blue">issued <font color="blue">patents may</font></font> be too narrow in scope to <font color="blue">provide us</font>     with a <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent position</font> is uncertain and includes     complex factual and <font color="blue">legal issues</font>, including the existence of prior art that     may preclude or limit the scope of <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">inventors may</font>     have filed earlier <font color="blue">patent <font color="blue">applications</font></font> of which we are unaware and which may     prevent our <font color="blue"><font color="blue">applications</font> from</font> being granted</td>
    </tr>
    <tr>
      <td>Patent examiners and third     <font color="blue">parties may</font> object to the validity or scope of some or all of our claims</td>
    </tr>
    <tr>
      <td>Any of the patents that may be issued to us will expire <font color="blue">twenty years</font> after     they were first filed</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>or <font color="blue">others may</font> institute <font color="blue">challenges</font> against the validity or     <font color="blue">enforceability</font> of any patent owned by us, and if successful our <font color="blue">patents may</font>     be denied, rendered unenforceable, or invalidated</td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">litigation</font> to     uphold the validity of patents, and to protect and <font color="blue">prevent <font color="blue">infringement</font></font> of     patents can be substantial</td>
    </tr>
    <tr>
      <td>Maintaining, prosecuting, and enforcing a patent     <font color="blue">portfolio might</font> require funds that may not be available</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue"><font color="blue">adequately</font> protect</font> the aspects of our treatment     protocols that are not subject to <font color="blue">patent protection</font>, or are subject to only     limited  patent  protection</td>
    </tr>
    <tr>
      <td>Furthermore,  <font color="blue">competitors</font> and <font color="blue">others may</font>     in<font color="blue">dependent</font>ly develop similar or more advanced <font color="blue">treatment protocols</font> and     <font color="blue">technologies</font>, may design around aspects of our <font color="blue">technology</font>, or <font color="blue">may discover</font>     or duplicate our <font color="blue">trade secrets</font> and <font color="blue"><font color="blue">proprietary</font> methods</font></td>
    </tr>
    <tr>
      <td>To the extent we utilize processes and <font color="blue">technology</font> that <font color="blue">constitute</font> trade     secrets under <font color="blue">applicable laws</font>, we must implement <font color="blue">appropriate</font> levels of     security for those <font color="blue">trade secrets</font> to secure the protection of such laws,     which we may not do <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>For some of our <font color="blue"><font color="blue">proprietary</font> rights</font>, we may     need to <font color="blue">secure assignments</font> of rights from in<font color="blue">dependent</font> contractors and third     parties to perfect our rights, and if we fail to do so they may retain     <font color="blue">ownership rights</font> in the <font color="blue"><font color="blue">intellectual property</font> upon which</font> our business is     based</td>
    </tr>
    <tr>
      <td><font color="blue">Policing  </font>compliance  with  our <font color="blue">confidential</font>ity <font color="blue">agreement</font>s and     <font color="blue">unauthorized use</font> of our <font color="blue">technology</font> is <font color="blue">difficult</font>, and we may be unable to     determine <font color="blue">whether piracy</font> of our <font color="blue">technology</font> has occurred</td>
    </tr>
    <tr>
      <td>In addition, the     laws of many <font color="blue">foreign countries</font> do not protect <font color="blue"><font color="blue">proprietary</font> rights</font> as fully as     the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>While we have not had any <font color="blue">significant</font> issues to date, the loss of any     of our <font color="blue">trade secrets</font> or <font color="blue"><font color="blue">proprietary</font> rights</font> which may be <font color="blue">protected under</font> the     <font color="blue">foregoing <font color="blue">intellectual property</font> safeguards may</font> result in the loss of our     <font color="blue">competitive</font> advantage over present and potential <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Confidentiality </font><font color="blue">agreement</font>s with employees, licensees and <font color="blue">others may</font> not     <font color="blue">adequately</font>  prevent  <font color="blue">disclosure</font> of <font color="blue">trade secrets</font> and other <font color="blue">proprietary</font>     information          In order to protect our <font color="blue">proprietary</font> <font color="blue">technology</font> and processes, we rely     in part <font color="blue">on <font color="blue">confidential</font>ity provisions</font> in our <font color="blue">agreement</font>s with employees,     licensees,  treating  physicians  and others</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s may not     <font color="blue">effective</font>ly prevent <font color="blue">disclosure</font> of <font color="blue">confidential</font> information and may not     provide  an <font color="blue">adequate remedy</font> in the event of unauthorized <font color="blue">disclosure</font> of     <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">others may</font> in<font color="blue">dependent</font>ly discover     trade  secrets  and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Costly and time-consuming     <font color="blue">litigation</font> could be <font color="blue">necessary</font> to enforce and determine the scope of our     <font color="blue">proprietary</font>  rights,  and  failure  to obtain or maintain trade secret     protection <font color="blue">could <font color="blue">adversely</font> affect</font> our <font color="blue">competitive</font> business position</td>
    </tr>
    <tr>
      <td>To date     we have had one instance, in <font color="blue">February </font>2004, in which it was <font color="blue">necessary</font> to     send  a <font color="blue">formal demand</font> to cease and <font color="blue">desist using</font> our protocols to treat     patients to a <font color="blue">consultant</font> who had signed a <font color="blue">confidential</font>ity <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>He     <font color="blue">subsequently complied with</font> the demand and signed an innovation, <font color="blue">proprietary</font>     information and <font color="blue">confidential</font>ity <font color="blue">agreement</font>, and an <font color="blue">intellectual property</font>     assignment <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue"><font color="blue">adequately</font> protect</font> our other <font color="blue">intellectual property</font>     rights, <font color="blue"><font color="blue">which could</font> limit</font> our ability to compete          While we believe we have <font color="blue">proprietary</font> ownership, assigned or licensed     rights in <font color="blue">intellectual property</font> which is capable of <font color="blue">protection under federal</font>     trademark, copyright and/or patent laws, and under state laws regarding     trade  secrets,  we may not have taken, or in the <font color="blue">future may</font> not take,     <font color="blue">appropriate</font> legal measures, and may not be able to <font color="blue">adequately</font> secure the     <font color="blue">necessary</font> protections for our <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>We currently have no     issued US <font color="blue">patents protecting</font> our PROMETA protocols, and have not yet     registered all of our <font color="blue">trademarks</font> or <font color="blue">copyrights</font> and, until we do                                         25       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>so, we <font color="blue">must rely on various</font> state and <font color="blue">common law rights</font> for <font color="blue">enforcement</font> of     the rights to <font color="blue">exclusive use</font> of our <font color="blue">trade secrets</font>, trademark and <font color="blue">copyrights</font></td>
    </tr>
    <tr>
      <td>Although  Hythiam^^®  is  a  registered  trademark, our trademark     <font color="blue">applications</font> for our PROMETA™ <font color="blue">trademarks</font> are pending before the US Patent     and Trademark Office, and we have not yet been granted <font color="blue">registration</font> for     these marks</td>
    </tr>
    <tr>
      <td>If our trademark <font color="blue">registration</font>s are objected to or denied that     may impact our ability to use and protect our brand names and company and     <font color="blue">product identity</font></td>
    </tr>
    <tr>
      <td>Although we have applied for <font color="blue">trademarks</font> for some of our brand names,     and patents on some of our <font color="blue">technology</font>, in the future we may decide not to     <font color="blue">secure federal protection</font> of certain <font color="blue">copyrights</font>, <font color="blue">trademarks</font> or patents to     which we may be entitled</td>
    </tr>
    <tr>
      <td>Failure to do so, in the case of <font color="blue">copyrights</font> and     <font color="blue">trademarks</font>, may reduce our access to the courts, and to <font color="blue">certain remedies</font> of     <font color="blue">statutory damages</font> and attorneys’ fees, to which we may be entitled in the     event of a violation of our <font color="blue">proprietary</font> and <font color="blue">intellectual rights by third</font>     parties</td>
    </tr>
    <tr>
      <td>Similarly, the failure to seek issuance of any patents to which we     may be <font color="blue">entitled may</font> result in loss of <font color="blue">patent protection</font> should a <font color="blue">third party</font>     copy the patentable <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The loss of any <font color="blue"><font color="blue">proprietary</font> rights</font> which are     <font color="blue">protectable under</font> any of the <font color="blue">foregoing <font color="blue">intellectual property</font> safeguards may</font>     result in the loss of a <font color="blue">competitive</font> advantage over present or potential     <font color="blue">competitors</font>, with a resulting decrease in revenues and <font color="blue">profitability</font> for us</td>
    </tr>
    <tr>
      <td>There is no guarantee that such a loss of <font color="blue">competitive</font> advantage could be     remedied or <font color="blue">overcome by us at</font> a price which we would be willing or able to     pay, <font color="blue">which could</font> have a material adverse effect on our <font color="blue">operations</font> and could     <font color="blue">adversely</font> affect our revenues and earnings</td>
    </tr>
    <tr>
      <td>We may be subject to claims that we infringe the <font color="blue">intellectual property</font>     rights of others, and <font color="blue">unfavorable outcomes could harm</font> our business          Our  future  <font color="blue">operations</font>  may  be subject to claims, and potential     <font color="blue">litigation</font>, arising from our alleged <font color="blue">infringement</font> of patents, <font color="blue">trade secrets</font>     or <font color="blue">copyrights</font> owned by other <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We intend to fully <font color="blue">comply with</font>     the law in avoiding such <font color="blue">infringement</font>s</td>
    </tr>
    <tr>
      <td>However, within the healthcare, drug     and bio-<font color="blue">technology</font> industry, established companies have <font color="blue">actively pursued</font>     such <font color="blue">infringement</font>s, and have <font color="blue">initiated such</font> claims and <font color="blue">litigation</font>, which has     made the entry of <font color="blue">competitive</font> products more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Court-ordered injunctions may <font color="blue">prevent us from</font> bringing new products to     market, and the outcome of <font color="blue">litigation</font> and any resulting loss of revenues and     expenses of <font color="blue">litigation</font> may substantially affect our ability to meet our     expenses and continue <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Industry       The  <font color="blue">healthcare industry</font> in which we operate is subject to substantial     <font color="blue">regulation by</font> state and federal authorities, <font color="blue">which could</font> hinder, delay or     <font color="blue">prevent us from</font> commercializing our protocols          The <font color="blue">healthcare industry</font> is <font color="blue">highly regulated</font> and continues to undergo     <font color="blue">significant</font> changes as third-party payors, such as Medicare and Medicaid,     traditional indemnity insurers, managed care <font color="blue">organizations</font> and other private     payors  increase  efforts to control cost, <font color="blue">utilization</font> and delivery of     <font color="blue">healthcare services</font></td>
    </tr>
    <tr>
      <td>Although our licensees do not <font color="blue">currently bill</font> or seek     <font color="blue"><font color="blue">reimbursement</font> from</font> Medicare, Medicaid or other <font color="blue">government</font>al <font color="blue">organizations</font>     for  the  treatment  of  patients  using <font color="blue">the PROMETA </font>protocols, we are     <font color="blue">nevertheless</font>  subject  to the overall effect of the changes created by     <font color="blue">increased cost control</font> and <font color="blue">financial pressures on</font> the industry</td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font>companies are subject to extensive and <font color="blue">complex federal</font>,     state and local laws, <font color="blue">regulations</font> and <font color="blue"><font color="blue">judicial <font color="blue">decisions</font></font> governing various</font>     <font color="blue">matters such as</font> the licensing and <font color="blue">certification</font> of <font color="blue">facilities</font> and personnel,     the conduct of <font color="blue">operations</font>, billing policies and practices, policies and     practices  with  regard  to  patient  privacy and <font color="blue">confidential</font>ity, and     <font color="blue">prohibitions on payments</font> for the referral of business and self-referrals</td>
    </tr>
    <tr>
      <td>There are federal and state laws, <font color="blue">regulations</font> and <font color="blue">judicial <font color="blue">decisions</font></font> that     govern patient referrals, physician financial <font color="blue">relationships</font>, submission of     healthcare claims and <font color="blue">inducement</font> to <font color="blue">beneficiaries</font> of <font color="blue">federal healthcare</font>     programs</td>
    </tr>
    <tr>
      <td>Many  states prohibit business <font color="blue"><font color="blue">corporations</font> from practicing</font>     medicine, employing or maintaining <font color="blue">control over physicians</font> who practice     medicine, or engaging in certain business practices, such as splitting fees     <font color="blue">with <font color="blue">healthcare providers</font></font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">healthcare laws</font> and <font color="blue">regulations</font> applicable     to our business are complex, applied broadly and subject to <font color="blue">interpretation</font>     by  courts and <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>Our failure, or the failure of our     licensees, to <font color="blue">comply with</font> these <font color="blue">healthcare laws</font> and <font color="blue">regulations</font> could create     <font color="blue">liability</font> for us and <font color="blue">negatively impact</font> our business</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>     In  addition,  the  Food and Drug Administration (FDA), regulates     <font color="blue">development</font>,  testing,  labeling, manufacturing, marketing, promotion,     distribution, record-keeping and reporting <font color="blue">requirements</font> for <font color="blue">prescription</font>     drugs, medical devices and biologics</td>
    </tr>
    <tr>
      <td>Other <font color="blue">regulatory</font> <font color="blue">requirements</font> apply to     dietary  <font color="blue">supplements</font>  (including  vitamins)</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with laws and     <font color="blue">regulations</font>  enforced  by the FDA and other <font color="blue">regulatory</font> agencies may be     required relative to our protocols or any other <font color="blue">medical products</font> or services     developed  or  used  by us</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> <font color="blue">applicable laws</font> and     <font color="blue">regulations</font> may result in various adverse <font color="blue">consequences</font>, including withdrawal     of  our protocols from the market, the imposition of civil or criminal     sanctions, or the required <font color="blue">modification</font> or redesign of our protocols</td>
    </tr>
    <tr>
      <td>We may     not have the <font color="blue">financial resources</font> to modify our protocols or implement new     <font color="blue">techniques</font></td>
    </tr>
    <tr>
      <td>Accordingly, our ability to market our protocols in compliance     with  applicable  laws and <font color="blue">regulations</font> may be a <font color="blue">threshold test</font> for our     survival</td>
    </tr>
    <tr>
      <td>We believe that this industry <font color="blue">will continue</font> to be subject to increasing     regulation, political and <font color="blue">legal action</font> and <font color="blue">pricing pressures</font>, the scope and     effect  of  which we <font color="blue">cannot predict</font></td>
    </tr>
    <tr>
      <td><font color="blue">Legislation </font>is <font color="blue">continuously</font> being     proposed, enacted and <font color="blue">interpreted at</font> the federal, state and <font color="blue">local levels</font> to     regulate  healthcare  delivery  and  <font color="blue">relationships</font>  between  and among     <font color="blue">participants</font> in the <font color="blue">healthcare industry</font></td>
    </tr>
    <tr>
      <td>Any such changes <font color="blue">could prevent us</font>     <font color="blue">from marketing</font> some or all of our products and services for a period of time     or <font color="blue">permanently</font></td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">regulatory</font> and investigative <font color="blue">proceedings</font>, which may     find that our policies and procedures do not fully <font color="blue">comply with</font> complex and     changing healthcare <font color="blue">regulations</font>          While we have <font color="blue">established policies</font> and procedures that we believe will     be sufficient to ensure that we operate in substantial <font color="blue">compliance with</font>     <font color="blue">applicable laws</font>, <font color="blue">regulations</font> and <font color="blue">requirements</font>, the criteria are <font color="blue">often vague</font>     and subject to change and <font color="blue">interpretation</font></td>
    </tr>
    <tr>
      <td>We may become the subject of     <font color="blue">regulatory</font> or other <font color="blue"><font color="blue">investigation</font>s</font> or <font color="blue">proceedings</font>, and our <font color="blue">interpretation</font>s     of <font color="blue">applicable laws</font> and <font color="blue">regulations</font> may be challenged</td>
    </tr>
    <tr>
      <td>The defense of any     such  challenge  could  result  in substantial cost and a diversion of     <font color="blue">management</font>’s time and attention</td>
    </tr>
    <tr>
      <td>Thus, any <font color="blue">such challenge</font> could have a     material adverse effect on our business, <font color="blue">regardless</font> of whether it ultimately     is  successful</td>
    </tr>
    <tr>
      <td>If  we  fail to <font color="blue">comply with</font> any <font color="blue">applicable laws</font>, or a     de<font color="blue">termination</font> is made that we have failed to <font color="blue">comply with</font> these laws, our     <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The  promotion  of  our  <font color="blue">protocols may</font> be found to <font color="blue">violate federal law</font>     concerning “off-label” uses of <font color="blue">prescription</font> drugs, <font color="blue">which could</font> prevent us     <font color="blue">from marketing</font> our protocols          The Food Drug &amp; Cosmetic (FDC) Act, requires that <font color="blue">prescription</font> drugs be     approved  for  a <font color="blue">specific medical indication by</font> the FDA prior to their     marketing  in  interstate  commerce</td>
    </tr>
    <tr>
      <td>In addition, promotion of dietary     <font color="blue">supplements</font> for uses beyond those <font color="blue">permitted by law may</font> be <font color="blue">treated as</font> the     <font color="blue">unlawful promotion</font> of <font color="blue">drugs absent</font> FDA approval</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Violations </font>of the FDC Act     </font>may result in either civil (seizure or injunction) or <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">procedural medical protocols call</font> for the use of <font color="blue">prescription</font> drugs for     the treatment of <font color="blue">chemical dependence</font> and drug <font color="blue">addiction</font>, <font color="blue">conditions</font> not     approved for use in the drugs’ official labeling, and <font color="blue">physicians prescribe</font>     and use these drugs when <font color="blue">treating patients using</font> our protocols</td>
    </tr>
    <tr>
      <td>In addition,     our protocols include the use of nutritional <font color="blue">supplements</font></td>
    </tr>
    <tr>
      <td><font color="blue">While the FDA     </font><font color="blue">generally</font> does not <font color="blue">regulate licensed physicians</font> who <font color="blue">prescribe approved drugs</font>     for  non-approved  or  “off-label” uses in the in<font color="blue">dependent</font> practice of     medicine, our promotion of our <font color="blue">protocols through <font color="blue">advertising</font></font> and other means     may be found to violate FDA <font color="blue">regulations</font> or the FDC Act</td>
    </tr>
    <tr>
      <td>The FDA has broad     <font color="blue">discretion</font> in <font color="blue">interpreting</font> those <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>determines that our     promotion of our medical <font color="blue">treatment protocols</font> violates the FDC Act or brings     an  <font color="blue">enforcement</font>  action  against  us  for violating <font color="blue">the FDC Act or FDA     </font><font color="blue">regulations</font> that is successful, our promotion of our <font color="blue">protocols will</font> have to     stop and we may be unable to continue operating under our current business     model</td>
    </tr>
    <tr>
      <td>Even if we defeat any FDA challenge, the <font color="blue">expenses associated with</font>     defending the claim or <font color="blue">negative publicity concerning</font> the off-label use of     drugs in our protocols <font color="blue">could <font color="blue">adversely</font> affect</font> our business and results of     operation</td>
    </tr>
    <tr>
      <td><font color="blue">Treatment </font>using our <font color="blue">protocols may</font> be found to require review or approval,     <font color="blue">which could</font> delay or prevent the study or use of our protocols          The FDA asserts <font color="blue"><font color="blue">jurisdiction</font> over</font> many <font color="blue"><font color="blue">clinical trial</font>s</font>, or <font color="blue">experiments</font>,     in which a drug is <font color="blue">administered</font> to <font color="blue">human subjects</font></td>
    </tr>
    <tr>
      <td><font color="blue">Hospitals </font>and clinics     have established Institutional Review Boards, or IRBs, to review and approve     clinical  trials using <font color="blue"><font color="blue">investigation</font>al</font> <font color="blue">treatments</font> in their <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue"><font color="blue">investigation</font>s</font> involving new drugs or off-label uses for approved     <font color="blue">drugs must</font> be the subject of an FDA <font color="blue"><font color="blue">investigation</font>al</font> New Drug exemption     (IND)</td>
    </tr>
    <tr>
      <td>Use of our                                         27       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font><font color="blue">treatment protocol by</font> individual physicians in treating their <font color="blue">patients may</font>     be found to <font color="blue">constitute</font> a <font color="blue">clinical trial</font> or <font color="blue">investigation</font> that requires IRB     review or an IND FDA has <font color="blue">broad authority</font> in <font color="blue">interpreting</font> and applying its     <font color="blue">regulations</font>, so it may find that use of our <font color="blue">protocols by</font> our licensees or     <font color="blue">collection</font> of <font color="blue">outcomes data on</font> that use <font color="blue">constitute</font>s a clinical <font color="blue">investigation</font>     subject to <font color="blue">IRB and FDA </font><font color="blue">jurisdiction</font> and may take <font color="blue">enforcement</font> action against     us</td>
    </tr>
    <tr>
      <td><font color="blue">Individual </font>hospitals and <font color="blue"><font color="blue">physicians may</font> also submit</font> their use of our     protocols in treatment to their IRBs and individual IRBs may find that use     to be a <font color="blue">clinical trial</font> that requires FDA approval or they <font color="blue">may prohibit</font> or     place <font color="blue">restrictions</font> on that use</td>
    </tr>
    <tr>
      <td>Any of these results may <font color="blue">adversely</font> affect     our business and the ability of our customers to use our protocols</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> the Federal Trade Commission Act or similar state     laws could result in sanctions or limit the claims we can make          The  company’s  promotional  <font color="blue">activities</font>  and materials, including     <font color="blue">advertising</font> to consumers and physicians, and <font color="blue">materials provided</font> to licensees     for their use in promoting our protocols, are <font color="blue">regulated by</font> the Federal Trade     Commission (FTC) under the FTC Act, which prohibits unfair and <font color="blue">deceptive</font>     acts  and  practices,  including claims which are false, misleading or     in<font color="blue">adequately</font>  <font color="blue"><font color="blue">substantiate</font>d</font></td>
    </tr>
    <tr>
      <td>The FTC typically requires competent and     <font color="blue">reliable scientific tests</font> or studies to <font color="blue">substantiate</font> express or implied     claims that a product or service is <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FTC </font>were to interpret     our <font color="blue">promotional materials as</font> making express or implied claims that our     protocols  are  <font color="blue">effective</font>  for  the  treatment  of alcohol, cocaine or     <font color="blue">methamphetamine</font>  <font color="blue">addiction</font>,  it  may find that we do not have adequate     <font color="blue">substantiation</font>  for such claims</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> the FTC Act or     similar laws enforced by state attorneys general and other state and local     <font color="blue">officials could</font> result in <font color="blue">administrative</font> or <font color="blue">judicial orders limiting</font> or     <font color="blue">eliminating</font> the claims we can make about our protocols, and other sanctions     including fines</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">practices may</font> be found to <font color="blue">constitute</font> illegal fee-splitting or     <font color="blue">corporate practice</font> of medicine, which may lead to penalties and <font color="blue">adversely</font>     affect our business          Many states, including <font color="blue">California </font>in which our principal executive     offices are located, have laws that prohibit business <font color="blue">corporations</font>, such as     us, from practicing medicine, exercising control over medical judgments or     <font color="blue">decisions</font>  of physicians, or engaging in certain <font color="blue">arrangements</font>, such as     <font color="blue">employment</font> or fee-splitting, with physicians</td>
    </tr>
    <tr>
      <td>Courts, <font color="blue">regulatory</font> authorities     or other parties, including physicians, may assert that we are engaged in     the unlawful <font color="blue">corporate practice</font> of medicine by providing <font color="blue">administrative</font> and     <font color="blue">ancillary services</font> in <font color="blue"><font color="blue">connection</font> with</font> our protocols, or that licensing our     <font color="blue">technology</font>  for a portion of the <font color="blue">patient fees</font>, or <font color="blue">subleasing space</font> and     providing turn-key business <font color="blue">management</font> to <font color="blue">affiliated medical groups</font> in     exchange  for  <font color="blue">management</font>  and  licensing  fees,  <font color="blue">constitute</font>  improper     fee-splitting, in which case we could be subject to civil and criminal     penalties, our <font color="blue">contracts could</font> be <font color="blue">found legally invalid</font> and unenforceable,     in whole or in part, or we could be required to <font color="blue">restructure</font> our <font color="blue">contractual</font>     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that this will not occur or, if it     does, that we would be able to <font color="blue">restructure</font> our <font color="blue">contractual</font> <font color="blue">arrangements</font> on     favorable terms</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">practices may</font> be found to violate anti-kickback, self-referral     or false claims laws, which may lead to penalties and <font color="blue">adversely</font> affect our     business          The <font color="blue">healthcare industry</font> is subject to extensive federal and state     <font color="blue">regulation with respect</font> to financial <font color="blue">relationships</font> and “kickbacks” involving     <font color="blue">healthcare providers</font>, physician self-referral <font color="blue">arrangements</font>, filing of false     claims and other fraud and <font color="blue">abuse issues</font></td>
    </tr>
    <tr>
      <td>Federal anti-kickback laws and     <font color="blue">regulations</font> prohibit certain offers, payments or receipts of <font color="blue">remuneration</font> in     return for (i) <font color="blue">referring patients covered by</font> Medicare, Medicaid or other     federal  <font color="blue">health care program</font>, or (ii) purchasing, leasing, ordering or     arranging for or <font color="blue">recommending</font> any service, good, item or <font color="blue">facility</font> for which     <font color="blue">payment may</font> be made by a federal <font color="blue">health care program</font></td>
    </tr>
    <tr>
      <td>In addition, federal     physician  self-referral legislation, commonly known as the Stark law,     <font color="blue">generally</font> prohibits a <font color="blue">physician from ordering certain services reimbursable</font>     by Medicare, Medicaid or other <font color="blue">federal healthcare</font> program from any entity     with which the physician has a <font color="blue">financial relationship</font></td>
    </tr>
    <tr>
      <td>While providers who     license our protocols currently do not seek such <font color="blue">third party</font> <font color="blue">reimbursement</font>     for <font color="blue">treatment using</font> our protocols, we anticipate they may do so in the     future</td>
    </tr>
    <tr>
      <td>In addition, many states have similar laws, some of which are not     limited to services reimbursed by <font color="blue">federal healthcare</font> programs</td>
    </tr>
    <tr>
      <td>Other federal     and state laws govern the submission of claims for <font color="blue">reimbursement</font>, or false     claims laws</td>
    </tr>
    <tr>
      <td>One of the <font color="blue">most prominent</font> of these laws is the federal False     Claims Act, and violations of other laws, such as the anti-kickback laws or     the FDA <font color="blue">prohibitions against promotion</font> of off-label uses of drugs, may also     be <font color="blue">prosecuted as violations</font> of the <font color="blue">False Claims Act</font></td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>     While we believe we have structured our <font color="blue">relationships</font> to <font color="blue">comply with</font>     all applicable <font color="blue">requirements</font>, federal or state <font color="blue">authorities may</font> claim that our     fee <font color="blue">arrangements</font>, <font color="blue">agreement</font>s and <font color="blue">relationships</font> with contractors, hospitals     and <font color="blue">physicians violate</font> these anti-kickback, self-referral or false claims     laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>These laws are broadly worded and have <font color="blue">been broadly</font>     <font color="blue">interpreted by courts</font></td>
    </tr>
    <tr>
      <td>It is often <font color="blue">difficult</font> to <font color="blue">predict how</font> these laws will     be applied, and they <font color="blue">potentially</font> subject many typical business <font color="blue">arrangements</font>     to <font color="blue">government</font> <font color="blue">investigation</font> and prosecution, which can be costly and time     consuming</td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of these laws are punishable by monetary fines, civil     and <font color="blue">criminal penalties</font>, exclusion from <font color="blue">participation</font> in <font color="blue">government</font>-sponsored     <font color="blue">health care program</font>s and <font color="blue">forfeiture</font> of amounts collected in violation of     such laws</td>
    </tr>
    <tr>
      <td>If our business     practices are found to violate any of these provisions, we may be unable to     <font color="blue">continue with</font> our <font color="blue">relationships</font> or implement our business plans, <font color="blue">which would</font>     have an adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be subject to healthcare anti-fraud initiatives, which may lead to     penalties and <font color="blue">adversely</font> affect our business          State and federal <font color="blue">government</font>s are devoting increased attention and     resources to anti-fraud initiatives against <font color="blue">healthcare providers</font>, taking an     expansive <font color="blue">definition</font> of fraud that includes receiving fees in <font color="blue">connection</font>     with a healthcare business that is found to violate any of the complex     <font color="blue">regulations</font> described above</td>
    </tr>
    <tr>
      <td>While to our knowledge we have not been the     subject  of  any  anti-fraud <font color="blue"><font color="blue">investigation</font>s</font>, if such a claim were made     defending our business practices could be time consuming and expensive, and     an adverse finding could result in substantial penalties or require us to     <font color="blue">restructure</font> our <font color="blue">operations</font>, which we may not be able to do <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Our use and <font color="blue">disclosure</font> of patient information is subject to privacy and     security <font color="blue">regulations</font>, which may result in <font color="blue">increased costs</font>          In  conducting  research  or providing <font color="blue">administrative</font> services to     <font color="blue">healthcare providers</font> in <font color="blue"><font color="blue">connection</font> with</font> the use of our protocols, we may     collect, use, maintain and <font color="blue">transmit patient</font> information in ways that will be     subject to many of the numerous state, federal and <font color="blue">international</font> laws and     <font color="blue">regulations</font> governing the <font color="blue">collection</font>, dissemination, use and <font color="blue">confidential</font>ity     of patient-identifiable health information, including the federal Health     Insurance Portability and Accountability Act (HIPAA) and related rules</td>
    </tr>
    <tr>
      <td>The     three  rules  that  were <font color="blue">promulgated pursuant</font> to HIPAA that <font color="blue">could most</font>     <font color="blue">significant</font>ly  affect  our  business  are the Standards for Electronic     Transactions,  or  Transactions  Rule;  the  Standards  for Privacy of     Individually Identifiable Health Information, or Privacy Rule; and the     Health Insurance Reform: Security Standards, or Security Rule</td>
    </tr>
    <tr>
      <td>HIPAA applies     to <font color="blue">covered entities</font>, which include most <font color="blue">healthcare <font color="blue">facilities</font></font> and health     plans that <font color="blue">will contract</font> for the use of our protocols and our services</td>
    </tr>
    <tr>
      <td>The     HIPAA  rules  require  <font color="blue">covered entities</font> to <font color="blue">bind contractors</font> like us to     <font color="blue">compliance with</font> certain burdensome HIPAA rule <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Other federal     and state <font color="blue">laws restricting</font> the use and protecting the privacy of patient     information <font color="blue">also apply</font> to our <font color="blue">licensees directly</font> and to us, either directly     or <font color="blue">indirectly</font></td>
    </tr>
    <tr>
      <td>The  HIPAA  Transactions Rule <font color="blue">establishes format</font> and <font color="blue">data content</font>     standards for eight of the <font color="blue">most common healthcare <font color="blue">transactions</font></font></td>
    </tr>
    <tr>
      <td>When we     perform billing and <font color="blue">collection</font> services on behalf of our licensees we may be     engaging in one of more of these standard <font color="blue">transactions</font> and will be required     to conduct those <font color="blue">transactions</font> in <font color="blue">compliance with</font> the required standards</td>
    </tr>
    <tr>
      <td>The     HIPAA Privacy Rule restricts the use and <font color="blue">disclosure</font> of patient information,     requires entities to safeguard that information and to <font color="blue">provide certain</font>     rights to <font color="blue">individuals with respect</font> to that information</td>
    </tr>
    <tr>
      <td>The HIPAA Security     Rule establishes elaborate <font color="blue">requirements</font> for <font color="blue">safeguarding patient</font> information     transmitted or <font color="blue">stored electronically</font></td>
    </tr>
    <tr>
      <td>We may be required to make costly     system  purchases  and  <font color="blue">modification</font>s  to  comply  with the HIPAA rule     <font color="blue">requirements</font> that are <font color="blue">imposed on us</font> and our failure to <font color="blue">comply may</font> result in     <font color="blue">liability</font> and <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td><font color="blue">Federal  </font>and  state  consumer  protection  laws are being applied     <font color="blue">increasingly</font>  by  the  FTC and state attorneys general to regulate the     <font color="blue">collection</font>, use and <font color="blue">disclosure</font> of personal or patient information, through     web  sites  or otherwise, and to regulate the <font color="blue">presentation</font> of web site     content</td>
    </tr>
    <tr>
      <td>Courts <font color="blue">may also adopt</font> the standards for fair information practices     <font color="blue">promulgated by</font> the FTC, which concern consumer notice, choice, security and     access</td>
    </tr>
    <tr>
      <td>Numerous other federal and state laws protect the <font color="blue">confidential</font>ity of     personal and patient information</td>
    </tr>
    <tr>
      <td>These laws in many cases are not preempted     by the HIPAA rules and may be subject to varying <font color="blue">interpretation</font>s by courts     and <font color="blue">government</font> agencies, creating <font color="blue">complex compliance issues</font> for us and our     licensees and <font color="blue">potentially</font> exposing us                                         29       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>to <font color="blue">additional</font> expense, adverse publicity and <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">countries also</font>     have, or are developing, <font color="blue">laws governing</font> the <font color="blue">collection</font>, use and <font color="blue">transmission</font>     of personal or patient information and these laws could create <font color="blue">liability</font> for     us or increase our cost of doing business</td>
    </tr>
    <tr>
      <td>We  may not be able to <font color="blue">profitably adapt</font> to the changing healthcare and     substance <font color="blue">dependence treatment</font> industry, which may reduce or eliminate our     <font color="blue">commercial opportunity</font>          <font color="blue">Healthcare </font><font color="blue">organizations</font>, public and private, continue to change the     manner in which they operate and pay for services</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, the     <font color="blue">healthcare industry</font> has been subject to <font color="blue">increasing levels</font> of <font color="blue">government</font>     regulation of <font color="blue">reimbursement</font> rates and capital expenditures, among other     things</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the likelihood of all future changes in the     healthcare  industry in general, or the substance <font color="blue">dependence treatment</font>     industry  in particular, or what impact they may have on our earnings,     <font color="blue">financial condition</font> or business</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Common Stock       Our <font color="blue">stock price may</font> be subject to substantial <font color="blue">volatility</font>, and you may lose     all or a substantial part of your <font color="blue">investment</font>          Our <font color="blue">common stock</font> is traded on <font color="blue">The Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>Over the last     year, it traded between dlra4dtta26 and dlra9dtta30 per share on limited and sporadic     volume ranging from <font color="blue">approximately</font> 14cmam900 to 1cmam449cmam400 shares per day</td>
    </tr>
    <tr>
      <td>As a     result,  the  current  price for our <font color="blue">common stock</font> on <font color="blue">the Nasdaq </font>is not     <font color="blue">necessarily</font> a <font color="blue">reliable indicator</font> of our <font color="blue">fair market value</font></td>
    </tr>
    <tr>
      <td>The price at     which our <font color="blue">common stock</font> will trade may be <font color="blue">highly volatile</font> and <font color="blue">may fluctuate</font>     as a result of a number of factors, including the number of <font color="blue">shares available</font>     for sale in the market, quarterly variations in our operating results,     actual  or anticipated <font color="blue">announcements</font> of new data, studies, products or     <font color="blue">services by us</font> or <font color="blue">competitors</font>, <font color="blue">regulatory</font> <font color="blue"><font color="blue">investigation</font>s</font> or de<font color="blue">termination</font>s,     <font color="blue">acquisitions</font> or <font color="blue">strategic alliances by us</font> or our <font color="blue">competitors</font>, recruitment or     <font color="blue">departures</font> of <font color="blue">key personnel</font>, the gain or loss of <font color="blue">significant</font> customers,     changes in the estimates of our operating performance, market <font color="blue">conditions</font> in     our industry and the <font color="blue">economy as</font> a whole</td>
    </tr>
    <tr>
      <td>Over one-third of our stock is <font color="blue">controlled by</font> a <font color="blue">single stockholder</font> who has     the ability to <font color="blue">substantially influence</font> the election of <font color="blue">directors</font> and the     outcome of <font color="blue">matters submitted</font> to <font color="blue">stockholders</font>          As of <font color="blue">December </font>31, 2005, Reserva Capital, LLC, a limited <font color="blue">liability</font>     company whose sole managing member is Terren S Peizer, our chairman and     chief executive officer, directly owned 13cmam700cmam000 shares, which represent     <font color="blue">approximately</font> 35prca of our 39cmam504cmam330 shares of outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Peizer presently and is expected to continue to have the ability     to <font color="blue">substantially influence</font> the election of our board of <font color="blue">directors</font> and the     outcome of all other <font color="blue">issues submitted</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The interests of     this <font color="blue">stockholder may</font> not <font color="blue">always coincide with</font> our interests or the interests     of other <font color="blue">stockholders</font>, and it may act in a manner that advances its best     interests and not <font color="blue">necessarily</font> those of other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>One consequence     to this substantial stockholder’s interest is that it may be <font color="blue">difficult</font> for     investors  to  remove  <font color="blue">management</font>  of the company</td>
    </tr>
    <tr>
      <td>It <font color="blue">could also deter</font>     <font color="blue">unsolicited takeovers</font>, including <font color="blue">transactions</font> in which <font color="blue">stockholders</font> might     otherwise  receive a premium for their <font color="blue">shares over then current market</font>     prices</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our <font color="blue">certificate</font> of <font color="blue">incorporation</font>, bylaws and <font color="blue">Delaware </font>law     could  discourage  a  change in control, and <font color="blue">adversely</font> affect existing     <font color="blue">stockholders</font>          Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and the <font color="blue">Delaware </font>General Corporation     Law <font color="blue">contain provisions</font> that may have the effect of making more <font color="blue">difficult</font> or     <font color="blue">delaying attempts by others</font> to obtain control of our company, even when     these <font color="blue">attempts may</font> be in the <font color="blue">best interests</font> of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font>     of <font color="blue">incorporation</font> also authorizes our board of <font color="blue">directors</font>, without stockholder     approval, to issue one or more series of preferred stock, <font color="blue">which could</font> have     voting and <font color="blue">conversion rights</font> that <font color="blue">adversely</font> affect or dilute the voting     power of the holders of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delaware </font>law also imposes <font color="blue">conditions</font>     on   certain   business   <font color="blue">combination</font>  <font color="blue">transactions</font>  with  “interested     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>”          These provisions and others that could be adopted in the <font color="blue">future could</font>     deter <font color="blue">unsolicited takeovers</font> or delay or prevent changes in our control or     <font color="blue">management</font>, including <font color="blue">transactions</font> in which <font color="blue">stockholders</font> <font color="blue">might otherwise</font>     receive a premium for their <font color="blue">shares over then current market</font> prices</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions  may  also  limit  the  ability  of <font color="blue">stockholders</font> to approve     <font color="blue">transactions</font> that they may deem to be in their <font color="blue">best interests</font></td>
    </tr>
    <tr>
      <td>30       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>We have never paid <font color="blue">cash dividends</font> and do not intend to do so          We have never declared or <font color="blue">paid <font color="blue">cash dividends</font> on</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We     currently plan to retain any earnings to finance the growth of our business     <font color="blue">rather than</font> to <font color="blue">pay <font color="blue">cash dividends</font></font></td>
    </tr>
    <tr>
      <td>Payments of any <font color="blue">cash dividends</font> in the     <font color="blue">future will depend on</font> our <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and     capital <font color="blue">requirements</font>, as well as other factors deemed <font color="blue">relevant by</font> our board     of <font color="blue">directors</font></td>
    </tr>
  </tbody>
</table>